Skip to Content

Label Changes for:

Tigan (trimethobenzamide hydrochloride) Injectable for Intramuscular Use Only

April 2008

Changes have been made to the CONTRAINDICATIONS and PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- April 2008


The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.

Summary View


Sections Modified Summary of Changes to Contraindications and Warnings



  • General
    • Adjustment of Dose in Renal Failure
  • Geriatric Use


The injectable form of Tigan is contraindicated in pediatric patients and in patients with known hypersensitivity to trimethobenzamide.